LONDON, UK / ACCESSWIRE / March 5, 2021 / Basilea has successfully brought two anti-infective drugs to the market. Lead product Cresemba continues to benefit from ongoing launches by multiple partners including Astellas (US) and Pfizer (ex-US). Longer-term value creation is dependent on crystallising the mid-/late-stage oncology portfolio. Three ongoing Phase II trials (FIDES-01/02/03) will define lead R&D asset derazantinib's utility in intrahepatic cholangiocarcinoma (iCCA; bile duct cancer), urothelial cancer and gastric cancer. Lisavanbulin, a unique, internally developed asset, has progressed into a proof-of-concept Phase II biomarker-driven trial in recurrent glioblastoma (GBM) (interim results expected H221). Our forecast profitability in 2022 is dependent on the late-stage clinical development strategy for derazantinib and lisavanbulin. We value Basilea at CHF1.17bn or CHF99 per share.
Our valuation is CHF1.17bn or CHF99 per share, from CHF1.14bn or CHF106 per share. We have made minor adjustments to the model and increased the probability of success for lisavanbulin to 35% from 20%, and derazantinib to 50% from 40%, reflecting pipeline progression and encouraging data readouts. Our core underlying assumptions are unchanged. Our valuation reflects CHF77.9m net debt at 31 December 2020, excluding the gross CHF45.75m post-period capital raise.
Click here to view the full report or here to sign up to receive research as it is published.
All reports published by Edison are available to download free of charge from its website
www.edisongroup.com
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Dr Susie Jana +44 (0)20 3077 5700 healthcare@edisongroup.com
Dr John Priestner +44 (0)20 3077 5700 healthcare@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-group-/
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited
View source version on accesswire.com:
https://www.accesswire.com/633450/Basilea-Pharmaceutica-BSLN-Derazantinib-Spearheads-Oncology-Portfolio
